Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II cabozantinib in metastatic GIST after imatinib and sunitinib
2014-000501-13Phase 2Completed
- Sponsor
- European Organisation for Research and Treatment of Cancer
- Start
- Sep 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of cabozantinib in gastrointestinal stromal tumor (GIST), sponsored by European Organisation for Research and Treatment of Cancer. Primary endpoint: Progression-free survival at 12 weeks (binary). Started Sep 2016; status: completed.
02
Drugs
cabozantinib
03
Conditions
gastrointestinal stromal tumor (GIST)
Beyond the preview
Go deeper on 2014-000501-13.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-000501-13.